Next Article in Journal
Computational Characterization of Single-Electron Transfer Steps in Water Oxidation
Next Article in Special Issue
Functionalizing NaGdF4:Yb,Er Upconverting Nanoparticles with Bone-Targeting Phosphonate Ligands: Imaging and In Vivo Biodistribution
Previous Article in Journal
Metal Coordination Complexes as Redox Mediators in Regenerative Dye-Sensitized Solar Cells
Previous Article in Special Issue
Cytotoxic Gold(I) Complexes with Amidophosphine Ligands Containing Thiophene Moieties
Open AccessReview

Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?

1
Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK
2
School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK
*
Author to whom correspondence should be addressed.
Inorganics 2019, 7(3), 31; https://doi.org/10.3390/inorganics7030031
Received: 29 November 2018 / Revised: 6 February 2019 / Accepted: 13 February 2019 / Published: 1 March 2019
After nearly 20 years of research on the use of ruthenium in the fight against cancer, only two Ru(III) coordination complexes have advanced to clinical trials. During this time, the field has produced excellent candidate drugs with outstanding in vivo and in vitro activity; however, we have yet to find a ruthenium complex that would be a viable alternative to platinum drugs currently used in the clinic. We aimed to explore what we have learned from the most prominent complexes in the area, and to challenge new concepts in chemical design. Particularly relevant are studies involving NKP1339, NAMI-A, RM175, and RAPTA-C, which have paved the way for current research. We explored the development of the ruthenium anticancer field considering that the mechanism of action of complexes no longer focuses solely on DNA interactions, but explores a diverse range of cellular targets involving multiple chemical strategies. View Full-Text
Keywords: ruthenium; anticancer; metal complex ruthenium; anticancer; metal complex
Show Figures

Figure 1

MDPI and ACS Style

Coverdale, J.P.C.; Laroiya-McCarron, T.; Romero-Canelón, I. Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates? Inorganics 2019, 7, 31.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop